Mirtazapin Kullanımına Bağlı Oluşan Geç Başlangıçlı Huzursuz Bacak Sendromu, İlacın Kesilme Sürecinde Karşılaşılan Çekilme Belirtileri; Olgu Sunumu

Huzursuz bacak sendromu, bacaklarda huzursuzluk hissi uyku ya da istirahat esnasında bacaklarda hissedilen rahatsız- lık, huzursuzluk, hareket ettirme ihtiyacı, uyuşma, karıncalanma bazen de tam olarak tanımlanamayan bir durumdur.Psikiyatride sıkça reçete edilen antidepresanlar, antipsikotikler ve duygudurum düzenleyicilerinin kullanılması sıra- sında genellikle tedavinin erken dönemlerinde ortaya çıkabilmektedir.Antidepresanların sonlandırılması sırasında kesilme belirtileri gelişebilmektedir. Bu yazıda mirtazapin kullanımı sıra- sında geç başlangıçlı huzursuz bacak sendromu ve tedavi sonlandırılması sırasında şiddetli kesilme belirtileri gelişenbir olgu sunulacak ve bu duruma yol açabilecek olası mekanizmalar tartışılacaktır.

Mirtazapine-Induced Late Onset Restless Leg Syndrome, Withdrawal Symptoms Encountered In The Process Of Termination; A Case Report

Restless legs syndrome is a characterized by feeling discomfort, needing to move, numbness, tingling at legs duringthe sleep or relaxing times. However, sometimes the symptoms of this syndrome can be indefinable. During the periodof using such prescription medicines which are antidepressants, antipsychotics and mood stabilizers in psychiatry,Restless legs syndrome could reveal its symptoms before the treatment. When the antidepressant treatment is end,cessation symptoms may develop. In this article, late-onset Restless legs syndrome during the using mirtazapine and a developing fact in the severe ces- sation symptoms during the period of stopping treatment have presented. Also some mechanisms which may createthis situation have been discussed.

PDF

___

1. Hening WA. Subjective and objective criteria in the diagnosis of the restless legs syndrome. SleepMedicine 2004; 5 (3): 285-292. 2. National Heart Lung and Blood Institute Working Group on Rest- less Legs Syndrome. Restless legs syndrome: detection and mana- gement in primary care. Am. Fam. Phys 2000; 62, 108-114. 3. Lloret P, Veronica M, Guitton B. Drugs associated With Restless Legs Syndrome: A Case/Noncase Study in the French Pharma- covigilance Database. Journal of Clinical Psychopharmacology 2012; 32(6): 824-827. 4. Berigan TR. Mirtazapine-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry 2001; Jun;3(3): 143. 5. De Boer T, Nefkens F, Van Helvoirt A. Differences in modulati- on of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists mirtazapine mianserin and idaxozan. J Pharmacol Exp Ther 1996; 277: 852-860. 6. Kim SW, Shin IS, Kim JM, et al. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychophar- macol 2008 Oct; 23(7): 615-20. 7. Bahk WM, Pae CU, Chae JH, et al. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci 2002; 56(2): 209-10 8. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008; 42(6): 841-6. 9. Chang CC, Shiah IC, Chang HA, et al. Does domperidone poten- tiate mirtazapine associated restless legs syndrome? Prog Neu- ropsychopharmacol Biol Psychiatry 2006; 30: 316-8. 10. Haddad P M, Anderson I M. Recognising and managing antidep- ressant discontinuation symptoms. Advances in Psychiatric treat- ment 2007; 13(6), 447-457. 11. Berigan TR. Mirtazapine-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry 2001; 3(3): 143.